Thread on Drug Development process ЁЯз╡

Hit like & Retweet for more learnings ! ЁЯТКЁЯзкЁЯй║ЁЯТЙ
@unseenvalue

Topics Covered :
1.Introduction to CRO,CDMO,CMO & CRAMS
2.Discovery
3.Clinical Trials
4.Commercialization and Surveillance
5.Success Rates
6.CRO
7.CMO
8.CDMO
9.CRAMS

1. Introduction :
What are CROs, CDMOs, CMOs and CRAMS? How are they different from each other and what value do they add to the Pharma Value Chain? To understand these concepts, we took a look at the drug discovery process.
The APIs manufactured by our Indian players lie at the end of this value chain. There is a whole process that comes before it that takes a lot more time and costs a lot of money.
On average, it takes about 10 to 15 years for a drug to make it to market. It costs hundreds of millions, if not billions of dollars to bring one drug to market.
A drug goes through 3 big phases on itтАЩs way to make it to market - the discovery phase, clinical testing phase and the commercialization phase. Once we understand these phases, it makes it easy to understand the role of CROs and CDMOs
2.Discovery:
The discovery of a new drug starts in the research lab where researchers study hundreds of diseases. They analyse what part of the body a disease affects and what reaction the body has to these diseases.
Once all the causes for the disease have been identified, they investigate what could stop the spread of the disease, what could reduce its effects and what could reverse its effects.
They examine thousands of compounds like natural compounds, synthetic compounds and even bio-engineered compounds that could help with curing or preventing a disease.
The process of narrowing down these compounds is very long. They test these compounds on cell cultures and animals and collect vast amounts of data on how these compounds react. They then narrow these options down to one compound which has the best chance of success to
make the drug out of. This process can take upto 6 years.

Once all this data has been collected, they file an Investigational New Drug (IND) Application with the US FDA. The US FDA reviews the IND within 6 months of filing. Once the IND is approved,
they have permission to test this drug on human volunteers.
3. Clinical Trials:
The drug now moves to the Clinical Trials phase. It will be the first time a novel drug will be given to human beings. The clinical trials itself take place in 3 phases.
In Phase 1, the focus is on safety. In Phase 2, they focus on the effectiveness of the drug and dosing. Phase 3 testing is the largest and is done to make sure that the drug is safe and effective for a wide variety of people. The clinical trial phase can last for 6-7 years.
In Phase 1 -the drug is given to 20-100 HEALTHY(not suffering from the disease) volunteers. This is done to test if the drug is safe for human beings to consume and does not cause any adverse reaction in the body.
In Phase 2, the drug is given to a larger group of patients (several 100) suffering from the disease and is undertaken to test if the drug is actually effective on the disease. The safety tests are also continued from Phase 1 to see if the drug has any adverse side effects.
In Phase 3, the drug is tested on 300-3000 volunteers who are suffering from the disease. The drug is given to people of different genders, age groups, ethnicities to determine if it is effective for a major portion of the population.
Once the Phase 3 trials are completed, the company files an NDA - New Drug Application. The NDA contains the data from all the clinical trials for the FDA to review.
4. Commercialization and Surveillance:
If the FDA approves the NDA, the company can manufacture and market the drugs to the public. But the testing does not end here. The drug now moves into Phase 4 testing.
In Phase 4, the drug which is being sold to the public is continuously monitored to see if it is having the intended effect on the public and not causing any adverse side effects. If it does have any adverse effects, the drug is recalled.
5. Success Rates:
Approximately 70% of the drugs move from Phase 1 to Phase 2, 33% move from Phase 2 to Phase 3, 25-30% move from Phase 3 to Phase 4. About 70-90% of drugs in Phase 4 are successful in staying in the market.
CRO & CDMO :
So where do the CROs and CDMOs come in? Contract research organizations help with the first 2 phases whereas Contract development and manufacturing organizations help with the last 2 phases
6. CROs
CROs support the innovators by providing services from drug discovery right up to commercialization. They provide services like target discovery, pre clinical trials, management of clinical trials, help with regulatory filings and pharmacovigilance(Phase 4).
7. CMOs
Contract manufacturing organizations (CMO) on the other hand provide outsourced manufacturing solutions to the innovator. They are involved with the manufacturing of APIs and Formulations and oftentimes even involved with the final packaging of the product.
8.CDMO
CDMOs are a hybrid between these two. They come in at the clinical trials stage to help with development of the drug, small batch manufacturing for the trials, scaling up the manufacturing process for commercial production, large scale manufacturing and packaging of drugs
9. CRAMS
Finally there are players who provide all the above services right from drug discovery to manufacture and packaging. This is known as CRAMS - Contract Research and Manufacturing.

More from Value Educator

More from Uvlearnings

You May Also Like

рдХреНрдпрд╛ рдЖрдк рдЬрд╛рдирддреЗ рд╣реИрдВ рдХрд┐ рдХреНрдпрд╛ рд╣реИ, рдкрд┐рддреГ рдкрдХреНрд╖ рдореЗрдВ рдХреМрд╡реЗ рдХреЛ рдЦрд╛рдирд╛ рджреЗрдиреЗ рдХреЗ рдкреАрдЫреЗ рдХрд╛ рд╡реИрдЬреНрдЮрд╛рдирд┐рдХ рдХрд╛рд░рдг!

рд╢реНрд░рд╛рджреНрдз рдкрдХреНрд╖ рдореЗрдВ рдХреМрдУрдВ рдХрд╛ рдмрдбрд╝рд╛ рд╣реА рдорд╣рддреНрд╡ рд╣реИред рдХрд╣рддреЗ рд╣реИ рдХреМрдЖ рдпрдо рдХрд╛ рдкреНрд░рддреАрдХ рд╣реИ, рдпрджрд┐ рдЖрдкрдХреЗ рд╣рд╛рдереЛрдВ рджрд┐рдпрд╛ рдЧрдпрд╛ рднреЛрдЬрди рдЧреНрд░рд╣рдг рдХрд░ рд▓реЗ, рддреЛ рдРрд╕рд╛ рдорд╛рдирд╛ рдЬрд╛рддрд╛ рд╣реИ рдХрд┐ рдкрд┐рддрд░реЛрдВ рдХреА рдХреГрдкрд╛ рдЖрдкрдХреЗ рдКрдкрд░ рд╣реИ рдФрд░ рд╡реЗ рдЖрдкрд╕реЗ рдЦрд╝реБрд╢ рд╣реИред


рдХреБрдЫ рд▓реЛрдЧ рдХрд╣рддреЗ рд╣реИрдВ рдХреА рд╡реНрдпрдХреНрддрд┐ рдорд░рдХрд░ рд╕рдмрд╕реЗ рдкрд╣рд▓реЗ рдХреМрд╡реЗ рдХреЗ рд░реВрдк рдореЗрдВ рдЬрдиреНрдо рд▓реЗрддрд╛ рд╣реИ рдФрд░ рдЙрд╕реЗ рдЦрд╛рдирд╛ рдЦрд┐рд▓рд╛рдиреЗ рд╕реЗ рд╡рд╣ рднреЛрдЬрди рдкрд┐рддрд░реЛрдВ рдХреЛ рдорд┐рд▓рддрд╛ рд╣реИ

рд╢рд╛рдпрдж рд╣рдо рд╕рдмрдиреЗ рдЕрдкрдиреЗ рдШрд░ рдХреЗ рдХрд┐рд╕реА рдмрдбрд╝реЗ рдмреБрдЬрд╝реБрд░реНрдЧ, рдХрд┐рд╕реА рдкрдВрдбрд┐рдд рдпрд╛ рдЬреНрдпреЛрддрд┐рд╖рд╛рдЪрд╛рд░реНрдп рд╕реЗ рдпреЗ рд╕реБрдирд╛ рд╣реЛрдЧрд╛ред рд╡реЗ рдЕрдирдЧрд┐рдирдд рдХрд┐рд╕реНрд╕реЗ рд╕реБрдирд╛рдПрдВрдЧреЗ, рдХрд╣реЗрдВрдЧреЗ рдмрдбрд╝реЗ рдмреБрдЬрд╝реБрд░реНрдЧ рдХрд╣ рдЧрдП рдЗрд╕реАрд▓рд┐рдП рдРрд╕рд╛ рдХрд░рдирд╛

рд╢рд╛рдпрдж рд╣реА рд╣рдореЗрдВ рдХреЛрдИ рдЗрд╕рдХреЗ рдкреАрдЫреЗ рдХрд╛ рд╡реИрдЬреНрдЮрд╛рдирд┐рдХ рдХрд╛рд░рдг рдмрддрд╛ рд╕рдХреЗред

рд╣рдорд╛рд░реЗ рдЛрд╖рд┐ рдореБрдирд┐ рдФрд░ рдкреМрд░рд╛рдгрд┐рдХ рдХрд╛рд▓ рдореЗрдВ рд░рд╣рдиреЗ рд╡рд╛рд▓реЗ рд▓реЛрдЧ рдореБрд░реНрдЦ рдирд╣реАрдВ рдереЗ! рдХрднреА рд╕реЛрдЪрд┐рдпреЗрдЧрд╛ рдХреМрд╡реЛрдВ рдХреЛ рдкрд┐рддреГ рдкрдХреНрд╖ рдореЗрдВ рдЦрд┐рд▓рд╛рдИ рдЦреАрд░ рд╣рдорд╛рд░реЗ рдкреВрд░реНрд╡рдЬреЛрдВ рддрдХ рдХреИрд╕реЗ рдкрд╣реБрдВрдЪреЗрдЧреА?

рд╣рдорд╛рд░реЗ рдЛрд╖рд┐ рдореБрдирд┐ рд╡рд┐рджреНрд╡рд╛рди рдереЗ, рд╡реЗ рдЬреЛ рдмрд╛рдд рдХрд░рддреЗ рдпрд╛ рдХрд╣рддреЗ рдереЗ рдЙрд╕рдХреЗ рдкреАрдЫреЗ рдХреЛрдИ рди рдХреЛрдИ рд╡реИрдЬреНрдЮрд╛рдирд┐рдХ рдХрд╛рд░рдг рдЫреБрдкрд╛ рд╣реЛрддрд╛ рдерд╛ред

рдПрдХ рдмрд╣реБрдд рд░реЛрдЪрдХ рддрдереНрдп рд╣реИ рдкрд┐рддреГ рдкрдХреНрд╖, рднрд╛рджреЛ( рднрд╛рджреНрд░рдкрдж) рдкреНрд░рдХреГрддрд┐ рдФрд░ рдХрд╛рдХ рдХреЗ рдмреАрдЪред

рдПрдХ рдмрд╛рдд рдЬреЛ рдХрд╣ рд╕рдХрддреЗ рдХрд┐ рд╣рдо рд╕рдм рдиреЗ рд╕реНрд╡рддрдГ рдЙрдЧ рдЖрдпреЗ рдкреАрдкрд▓ рдпрд╛ рдмрд░рдЧрдж рдХрд╛ рдкреЗрдбрд╝/ рдкреМрдзрд╛ рдХрд┐рд╕реА рди рдХрд┐рд╕реА рджреАрд╡рд╛рд░, рдкреБрд░рд╛рдиреА

рдЗрдорд╛рд░рдд, рдкрд░реНрд╡рдд рдпрд╛ рдЕрдЯреНрдЯрд╛рд▓рд┐рдХрд╛рдУрдВ рдкрд░ рдЬрд╝рд░реВрд░ рджреЗрдЦрд╛ рд╣реЛрдЧрд╛ред рджреЗрдЦрд╛ рд╣реИ рди?

рдЬрд╝рд░рд╛ рд╕реЛрдЪрд┐рдпреЗ рдкреАрдкрд▓ рдпрд╛ рдмрд░рдЧрдж рдХреА рдмреАрдЬ рдХреИрд╕реЗ рдкрд╣реБрдВрдЪреЗ рд╣реЛрдВрдЧреЗ рд╡рд╣рд╛рдБ рддрдХ?┬ардЗрдирдХреЗ рдмреАрдЬ рдЗрддрдиреЗ рд╣рд▓реНрдХреЗ рднреА рдирд╣реАрдВ рд╣реЛрддреЗ рдХреЗ рд╣рд╡рд╛ рдЙрдиреНрд╣реЗрдВ рдЙрдбрд╝рд╛рдХреЗ рд▓реЗ рдЬрд╛ рд╕рдХреЗред
I just finished Eric Adler's The Battle of the Classics, and wanted to say something about Joel Christiansen's review linked below. I am not sure what motivates the review (I speculate a bit below), but it gives a very misleading impression of the book. 1/x


The meat of the criticism is that the history Adler gives is insufficiently critical. Adler describes a few figures who had a great influence on how the modern US university was formed. It's certainly critical: it focuses on the social Darwinism of these figures. 2/x

Other insinuations and suggestions in the review seem wildly off the mark, distorted, or inappropriate-- for example, that the book is clickbaity (it is scholarly) or conservative (hardly) or connected to the events at the Capitol (give me a break). 3/x

The core question: in what sense is classics inherently racist? Classics is old. On Adler's account, it begins in ancient Rome and is revived in the Renaissance. Slavery (Christiansen's primary concern) is also very old. Let's say classics is an education for slaveowners. 4/x

It's worth remembering that literacy itself is elite throughout most of this history. Literacy is, then, also the education of slaveowners. We can honor oral and musical traditions without denying that literacy is, generally, good. 5/x